ABHD6

Across TCGA pan-cancer cohorts, ABHD6 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ABHD6’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ABHD6 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ABHD6 is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

CCRCC, COAD, and LUAD are the cancer types where ABHD6 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ABHD6 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	−0.690	<.001	11	view →
COAD	Female	III,IV	−0.320	<.001	11	view →
LUAD	Female	All	−0.540	<.001	9	view →
LSCC	Female	II,III,IV	−0.494	<.001	9	view →
HNSC	All	All	+0.121	.020	3	view →
PDAC	Male	All	−0.271	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ABHD6–CCRCC

Open the CCRCC breakdown →